JPS6126914B2 - - Google Patents

Info

Publication number
JPS6126914B2
JPS6126914B2 JP54041274A JP4127479A JPS6126914B2 JP S6126914 B2 JPS6126914 B2 JP S6126914B2 JP 54041274 A JP54041274 A JP 54041274A JP 4127479 A JP4127479 A JP 4127479A JP S6126914 B2 JPS6126914 B2 JP S6126914B2
Authority
JP
Japan
Prior art keywords
reaction
antibiotic
absorption
culture
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54041274A
Other languages
Japanese (ja)
Other versions
JPS55133394A (en
Inventor
Tadayo Fujii
Shuzo Satoi
Naoki Muto
Mitsuo Hayashi
Akira Kodama
Masaru Kotani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Jozo KK
Original Assignee
Toyo Jozo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Jozo KK filed Critical Toyo Jozo KK
Priority to JP4127479A priority Critical patent/JPS55133394A/en
Priority to CA000349243A priority patent/CA1140877A/en
Priority to GB8011265A priority patent/GB2053895B/en
Priority to US06/137,292 priority patent/US4297486A/en
Priority to FR8007574A priority patent/FR2452932A1/en
Priority to DE19803013210 priority patent/DE3013210A1/en
Priority to CH5618/80A priority patent/CH648855A5/en
Priority to BE0/201867A priority patent/BE884925A/en
Publication of JPS55133394A publication Critical patent/JPS55133394A/en
Publication of JPS6126914B2 publication Critical patent/JPS6126914B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • C07H15/236Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/46Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin
    • C12P19/48Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin the cyclohexyl radical being substituted by two or more nitrogen atoms, e.g. destomycin, neamin
    • C12P19/485Having two saccharide radicals bound through only oxygen to non-adjacent ring carbons of the cyclohexyl radical, e.g. gentamycin, kanamycin, sisomycin, verdamycin, mutamycin, tobramycin, nebramycin, antibiotics 66-40B, 66-40D, XK-62-2, 66-40, G-418, G-52
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、ダクチロスポランジウム属に属する
アミノ糖抗生物質G―367―1生産菌による新規
アミノ糖抗生物質G―367―1およびその製造法
に関する。 本発明の新規アミノ糖抗生物質G―367―1
(以下、G―367―1という)の理化学的性質は次
の通りである。 融 点:130〜133℃ 〔α〕24 :+188.9゜(C=1.0 H2O) 元素分析 実測値 理論値 C=50.14 C=50.51 H= 7.60 H= 7.84 N=14.42 N=14.73 分子量:475(マススペクトルより) 分子式:C20H37N5O8 紫外部吸収スペクトル:水溶液にて220〜
360nmに特徴的な極大吸収を示さず、末端吸収を
示すのみである。 赤外部吸収スペクトル:(KBr法)第1図に示
す通りであつて、3350、2920、1660、1590、
1380、1140、1100、1050、1000、950−1cm付近の各
波長に吸収帯を有す。 核磁気共鳴スペクトル(水素核):第2図に示
す通り(D2O中、100MHz、内部基準DSS) 核磁気共鳴スペクトル(炭素核):D2O中、
25MHzにて、ジオキサンを内部基準として測定し
た。
The present invention relates to a novel amino sugar antibiotic G-367-1 produced by an amino sugar antibiotic G-367-1 producing bacterium belonging to the genus Dactyrosporandium and a method for producing the same. Novel amino sugar antibiotic G-367-1 of the present invention
The physical and chemical properties of (hereinafter referred to as G-367-1) are as follows. Melting point: 130-133°C [α] 24 D : +188.9° (C = 1.0 H 2 O) Elemental analysis Actual value Theoretical value C = 50.14 C = 50.51 H = 7.60 H = 7.84 N = 14.42 N = 14.73 Molecular weight : 475 (from mass spectrum) Molecular formula: C 20 H 37 N 5 O 8 Ultraviolet absorption spectrum: 220 ~ in aqueous solution
It does not show the characteristic maximum absorption at 360 nm, but only shows terminal absorption. Infrared absorption spectrum: (KBr method) As shown in Figure 1, 3350, 2920, 1660, 1590,
It has absorption bands at wavelengths around 1380, 1140, 1100, 1050, 1000, and 950 -1 cm. Nuclear magnetic resonance spectrum (hydrogen nuclei): As shown in Figure 2 (in D 2 O, 100 MHz, internal reference DSS) Nuclear magnetic resonance spectrum (carbon nuclei): in D 2 O,
Measurements were made at 25MHz using dioxane as an internal reference.

【表】 溶解性:水、メタノールに可溶、アセトン、ベ
ンゼン、酢酸エチル、クロロホルムに不溶。 呈色反応:ニンヒドリン反応、過マンガン酸カ
リウム脱色反応は陽性、エルソンモルガン反応、
ビウレツト反応は陰性。 色性状:白色粉末。 酸塩基の区別:塩基性、 薄層クロマトグラフイー(シリカゲル) 水(1:1:1)の下層 Rf=0.36 10%酢酸アンモニウム:メタノール(1:1) Rf=0.13 上記の理化学性状より、G―367―1は新規な
アミノ糖化合物と認められ、またその平面構造と
しては下記の構造が推定される新規化合物であ
る。 また、本発明のG―367―1の寒天希釈法によ
る抗菌スペクトル(最小発育阻止濃度を示す)は
次表の通りである。
[Table] Solubility: Soluble in water and methanol, insoluble in acetone, benzene, ethyl acetate, and chloroform. Color reaction: ninhydrin reaction, potassium permanganate decolorization reaction positive, Elson Morgan reaction,
Biuretz reaction was negative. Color properties: white powder. Distinction between acids and bases: Basic, thin layer chromatography (silica gel) Lower layer of water (1:1:1) Rf = 0.36 10% ammonium acetate: methanol (1:1) Rf = 0.13 From the above physical and chemical properties, G -367-1 is recognized as a novel amino sugar compound, and its planar structure is predicted to be as shown below. Further, the antibacterial spectrum (indicating the minimum inhibitory concentration) of G-367-1 of the present invention obtained by the agar dilution method is shown in the following table.

【表】【table】

【表】 さらに本発明の抗菌性、特にグラム陰性菌に付
する優れた抗菌性を有するG―367―1は、通常
医薬的に許容される鉱散や有機酸などの無毒性酸
付加塩の形で使用でき、例えば塩酸、ヨウ化水素
酸、硫酸、リン酸、炭酸、酢酸、フマル酸、リン
ゴ酸、クエン酸、マンデル酸、コハク酸、アスコ
ルビン酸、アスパラギン酸、グルタミン酸などの
酸類との塩の形で使用できる。また本発明のG―
367―1またはその無毒性酸付加塩は、例えば20
〜40mg用バイアルまたは20〜40mg含有アンプルと
して注射用製剤として適用される。 本発明のG―367―1生産放線菌は、静岡県富
士市の畑土壌より分離した放線菌G―367であつ
て、ダクチロスポランジウム
(Dactylosporangium)属に属するダクチロスポ
ランジウム・タイランデンセG367
(Dactylosporagiumthailandense G 367)と同
定、命名した(微生物受託番号通知書微生物受託
番号「微工研菌寄第4840号FERM―P No.
4840)。 以下にその菌学的諸性状について述べる。 〔〕 形態的性状 リンゴ酸カルシウム寒天培地〔Bact.Rev.21:
1(1957)〕上、30℃、3―7日間培養し、観察
した所見は次の通りである。 基生菌糸は曲線状または屈曲状で、分枝をなし
て伸長し、分断はせず、直径0.5〜0.8μであり、
気菌糸は形成しない。 基性菌糸に、大きさ1.5〜2.0×2.0〜2.5μの球
状または楕円状物体の着生が、寒天培地中に埋つ
た状態でみられる。 基生菌糸より短かい胞子のう柄を生じ、胞子の
うは指形で、寒天培地表面上に、1個または房状
に形成する。胞子のうの大きさは、1.0〜1.5×4.0
〜6.5μで、中に3〜4個の胞子がたてに一列に
入つている。 胞子は水中で運動性があり、形は球形、楕円形
または洋梨形を呈し、大きさは1.0〜1.5×1.5〜
2.5μであり、極性で房状の鞭毛を有している。 〔〕 ジアミノピメリン酸組成 全菌体分析によるジアミノピメリン酸は、メゾ
―型およびメゾ―型よりRm値の低いもの(slow
moving diaminopimellic acid)が検出された。 〔〕 各種培地における生育状態等 各種培地上で、30℃、14日間培養し、観察した
所見は次表の通りであり、オート・ミール寒天培
地上で末発育の気菌糸がわずかに形成される以外
は、気菌糸の形成は認められず、また胞子のうは
リンゴ酸カルシウム寒天培地上で良好、土壌寒天
培地〔J.gen.Microbiol.50:295(1968)〕上で、
中程度であり、その他の培地上ではわずか、また
はほとんど形成されなかつた。 なお、色の表示は、カラー・ハーモニー・マニ
アル(color Harmony Manual)第4版1958年
(container Corporation of America)による色
の分類に従つたものである。
[Table] Furthermore, G-367-1, which has antibacterial properties of the present invention, particularly has excellent antibacterial properties against Gram-negative bacteria, can be used in combination with non-toxic acid addition salts such as pharmaceutically acceptable mineral salts and organic acids. salts with acids such as hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, carbonic acid, acetic acid, fumaric acid, malic acid, citric acid, mandelic acid, succinic acid, ascorbic acid, aspartic acid, glutamic acid, etc. It can be used in the form of Also, the G-
367-1 or its non-toxic acid addition salt, for example 20
Applied as an injectable formulation in vials for ~40 mg or ampoules containing 20-40 mg. The G-367-1-producing actinomycete of the present invention is an actinomycete G-367 isolated from field soil in Fuji City, Shizuoka Prefecture, and is Dactylosporangium thailandense G367, which belongs to the genus Dactylosporangium.
(Dactylosporagiumthailandense G 367) was identified and named (Microorganism Accession Number Notification Microorganism Accession Number "FERM-P No. 4840 FERM-P No.
4840). The mycological properties are described below. [] Morphological properties Calcium malate agar medium [Bact.Rev.21:
1 (1957)], and the following findings were observed after culturing at 30°C for 3-7 days. The basal hyphae are curved or bent, branched and elongated, undivided, and 0.5 to 0.8 μ in diameter.
Aerial mycelium does not form. Spherical or ellipsoidal objects measuring 1.5 to 2.0 x 2.0 to 2.5 microns are observed on the basal hyphae, buried in the agar medium. It produces sporangial stalks that are shorter than the basal hyphae, and the sporangia are finger-shaped and are formed singly or in clusters on the surface of the agar medium. The size of the sporangium is 1.0 to 1.5 x 4.0
~6.5μ, with 3-4 spores arranged vertically in a row. The spores are motile in water and are spherical, oval, or pear-shaped, and the size is 1.0-1.5 x 1.5-
It is 2.5μ in length and has a polar, tufted flagellum. [] Diaminopimelic acid composition Diaminopimelic acid determined by whole bacterial cell analysis is meso-type and meso-type with a lower Rm value (slow
moving diaminopimellic acid) was detected. [] Growth status on various media, etc. Cultured on various media at 30℃ for 14 days, and observed findings are as shown in the table below.On oatmeal agar medium, a few terminally growing aerial mycelia are formed. No formation of aerial mycelium was observed, and sporangia were good on calcium malate agar, and on soil agar [J.gen.Microbiol.50:295 (1968)].
It was moderate, and little or no formation occurred on other media. Note that the color display is based on the color classification according to the Color Harmony Manual, 4th edition, 1958 (Container Corporation of America).

【表】【table】

【表】 〔〕 生理的性状 生理的諸性状は下記の通りである。 1 炭素源の資化性【table】 [] Physiological properties Physiological properties are as follows. 1 Assimilation of carbon sources

【表】【table】

【表】 2 生育温度範囲:20〜40℃ 3 脱脂牛乳:ペプトン化および凝固とともに陽
性 4 メラニン様色素の生成:陰性(チロシンおよ
びペプトン・イーストエキス・鉄寒天培地上) 5 スターチの加水分解:陽性 6 セルロースの分解:陰性 7 カゼインの分解:陽性 8 チロシンの分解:陰性 9 ゼラチンの液化:陽性 10 硫化水素の生成:弱い陽性 11 硝酸塩の還元:陽性 12 生育PH:PH5.5〜9.0 上記の通り、本菌G367の特徴としては、基生
菌糸に指形の胞子のうを着生し、胞子のう中に胞
子がたてに一列にならび、胞子に房状の鞭毛を有
していることにある。 このように、胞子のうを形成し、その中に鞭毛
を有する胞子を形成するものは、アクチノプラナ
セア(Actinoplanaceae)に属するものであつ
て、胞子のうが指形で、その中にたてに一列に胞
子が形成されるものは、ダクチロスポランジウム
属に属する。 さらに、本菌G367は有機培地上で、基生菌糸
が橙褐色ないし褐色を呈し、褐色の可溶性色素を
生ずる特徴を有することにより、ダクチロスポラ
ンジウム・タイランデンセ(Dactylosporangium
thailandense)〔Arch.Microbio1.58:42―52
(1967)〕に属するものと同定した。 よつて、本菌G367を、ダクチロスポランジウ
ム・タイランデンセG367と命名したものであ
る。 次いで、本発明の新規抗生物質たるG―367―
1を製造するに当つて例示すれば、上記のダクチ
ロスポランジウム属に属するG―367―1生産菌
を通常の微生物の培養に使用する培地成分を含む
培地にて好気的に培養することによつて得られ
る。培地としては、固型培地または液体培地が用
いられるが、特に大量生産のためには液体培地、
特に水性培地が適当である。 培地の栄養源としては、微生物の培養に通常用
いられるものが広く使用され得る。炭素源として
は同化可能な炭素化合物であればよく、例えばグ
ルコース、シユクロース、マルトース、スター
チ、デキストリン、モラツセなどが使用される。
窒素源としては利用可能な窒素化合物であればよ
く、例えばコーン・スチーブ・リカー、大豆粉、
綿実粉、小麦グルテン、ペプトン、肉エキス、酵
母エキス、カゼイン加水分解物、アンモニウム
塩、硝酸塩などが使用される。その他、リン酸
塩、マグネシウム、カルシウム、カリウム、ナト
リウム、コバルト、鉄、マンガンなどの塩類が必
要に応じて使用される。 培養温度は菌が発育し、G―367―1を生産す
る範囲内で適宜変更し得るが、特に好ましくは25
〜35℃である。培養時間は、条件によつて多少異
なるが、通常1100〜200時間程度であつて、G367
―1が最高力価に達する時期を見計つて適当な時
期に培養を終了すればよい。 このようにして得られたG―367―1生産菌の
液体培養の培養物中において、G―367―1は液
体部分に大部分産生されている。 次いでこのG―367―1生産菌の培養物からG
―367―1を採取するのであるかが、G―367―1
は水溶性の塩基性アミノ糖化合物であることを利
用して分離精製を行なうことが簡便である。また
生産されたG―367―1はバチルス・ズブチリス
PCI219を被検菌として、通常の寒天平板法によ
り活性区分の確認、および定量を行なつたもので
ある。 G―367―1の分離精製手段の一例を示すと次
の通りである。すなわちG―367―1生産菌を前
述の如く培養して得られる培養物から固形分を除
去して培養液を得るのであるが、G―367―1
がアミノ糖化合物であるためにその培養物のPHを
一旦酸性に調整し、これを中和して過してその
培養液を得ることが好ましく、次いでこの培養
液を陽イオン交換樹脂例えばアンバーライト
IRC―50(NH4 +型)のカラムにチヤージせしめ
て吸着せしめ、これより活性物質を2Nアンモニ
ア水にて溶出せしめ、さらにその溶出液を濃縮し
た後、そのPHを調整し、陽イオン交換樹脂例えば
CM―セフアデツクスC―25(NH4 +型)のカラム
にチヤージせしめて吸着せしめ、0〜0.35Nの濃
度勾配をもたせたアンモニア水にて溶出せしめ、
その活性画分を得、これを減圧濃縮し、凍結乾燥
することによりG―367―1の精製白色粉末を遊
離塩基の型にて得られる。またこの様にして得ら
れるG―367―1は薄層クロマトグラフイーにて
単一スポツトを示すものであることが簡便になし
得る。 次に本発明の実施例を挙げて具体的に説明する
が、本発明はこれにより何んら限定されるもので
はない。 実施例 1 デキストリン1%、グルコース1%、カゼイン
水解物0.5%、酵母エキス0.5%、炭酸カルシウム
0.1%を含有する培地(PH7.0)100mlを500ml容三
角フラスコに分取し、120℃、20分間加熱殺菌し
た。本培地10本に、各々ダクチロスポランジウ
ム・タイランデンセG367株の斜面培養物よりの
一白金耳を接種し、30℃、120時間振盪培養し
た。次いでこれを上記と同一組成の加熱殺菌した
培地20を含有する30容ジヤーフアーメンター
に移植し、30℃、72時間、300rpm、毎分20の
無菌空気の条件下で通気撹拌培養した。次いでデ
キストリン5%、グルコース0.5%、脱脂大豆粉
3%、炭酸カルシウム0.7%、塩化コバルト
1.3ppmを含有する加熱殺菌した培地(PH7.2)
200を含有する250容タンクに上記の培養物10
を移植し、30℃、120時間、250rpm、毎分100
の無菌空気の条件下通気撹拌培養し、培養物約
190を得た。 次いで、実施例2の如くして、その培養物より
G―367―1を分離精製するものである。 実施例 2 実施例1で得られた培養物を、12N硫酸水溶液
にてPH2に調整し、30分間撹拌した後、濃アンモ
ニア水にてPH7.0に調整し、さらにこれに過助
剤としてパーライト(商品名)4Kgを加えて過
し、次いで得られた培養液を、アンバーライト
IRC―50(ローム・アンド・ハース社製)NH4 +
型)10を充填したカラムにチヤージし、水洗し
た後、2Nアンモニア水20にて溶出せしめ、そ
の全溶出液を得、これを100mlまで減圧濃縮し
た。 次いでこの濃縮液を6N硫酸水溶液にてPH7.0に
調整し、これを、CM―セフアデツクスG―25
(フアルマシア・フアイン・ケミカル社製)
(NH4 +型)500mlを充填したカラム(径4cm)に
チヤージして活性物質を吸着せしめた。その後該
カラムを水洗後、0〜0.35Nの濃度勾配をもたせ
たアンモニア水5により溶出せしめ、溶出液を
20mlずつ分画した。各分画について、クロロホル
ム:メタノール:28%アンモニア水=1:1:1
の下層を展開溶媒とした薄層クロマトグラフイー
を行ない、ニンヒドリン発色により目的物を確認
した。その結果、第175画分より185画分がG―
367―1のみを含有したものであつた。次いでこ
の画分を回収、合せて減圧濃縮し、次いで凍結乾
燥して、白色粉末を得、さらにこれを、五酸化リ
ンの存在下で40℃、48時間減圧乾燥して、G―
367―1の精製白色粉末(遊離塩基)750mgを得
た。
[Table] 2 Growth temperature range: 20-40℃ 3 Skim milk: Positive with peptonization and coagulation 4 Production of melanin-like pigment: Negative (on tyrosine and peptone yeast extract iron agar medium) 5 Hydrolysis of starch: Positive 6 Cellulose decomposition: Negative 7 Casein decomposition: Positive 8 Tyrosine decomposition: Negative 9 Gelatin liquefaction: Positive 10 Hydrogen sulfide generation: Weak positive 11 Nitrate reduction: Positive 12 Growth pH: PH5.5-9.0 As above The characteristics of this fungus G367 are that it grows finger-shaped sporangia on the basal hyphae, the spores are arranged vertically in a single row, and the spores have tufted flagella. It is in. In this way, spores that form sporangia and have flagella inside them belong to the family of Actinoplanaceae, and the sporangium is finger-shaped and there are upright spores inside. Those in which spores are formed in a row belong to the genus Dactyrosporandium. Furthermore, this fungus G367 has the characteristic that the basal hyphae exhibit an orange-brown to brown color and produce a brown soluble pigment on an organic medium.
thailandense) [Arch.Microbio1.58:42-52
(1967)]. Therefore, this bacterium G367 was named Dactyrosporandium thailandense G367. Next, G-367-, the novel antibiotic of the present invention
For example, in producing 1, the G-367-1 producing bacteria belonging to the genus Dactylosporandium is aerobically cultured in a medium containing medium components used for the cultivation of ordinary microorganisms. obtained by. As a medium, a solid medium or a liquid medium is used, but especially for mass production, a liquid medium,
Particularly suitable are aqueous media. As the nutrient source for the medium, a wide variety of nutrients commonly used for culturing microorganisms can be used. The carbon source may be any assimilable carbon compound, such as glucose, sucrose, maltose, starch, dextrin, and molasses.
As a nitrogen source, any available nitrogen compound may be used, such as corn stew liquor, soybean flour,
Cottonseed flour, wheat gluten, peptone, meat extract, yeast extract, casein hydrolyzate, ammonium salts, nitrates, etc. are used. In addition, salts such as phosphate, magnesium, calcium, potassium, sodium, cobalt, iron, and manganese are used as necessary. The culture temperature can be changed as appropriate within the range that allows the bacteria to grow and produce G-367-1, but is particularly preferably 25
~35℃. The culture time varies slightly depending on the conditions, but is usually about 1100 to 200 hours.
-1 should reach its maximum titer and then terminate the culture at an appropriate time. In the liquid culture of the G-367-1 producing bacteria thus obtained, G-367-1 is mostly produced in the liquid portion. Next, from the culture of this G-367-1 producing bacteria, G
-367-1 is collected, but G-367-1
It is easy to separate and purify the compound by taking advantage of the fact that it is a water-soluble basic amino sugar compound. Also produced G-367-1 is Bacillus subtilis
Using PCI219 as the test bacterium, the active category was confirmed and quantified using the usual agar plate method. An example of separation and purification means for G-367-1 is as follows. That is, the solid content is removed from the culture obtained by culturing G-367-1 producing bacteria as described above to obtain a culture solution.
is an amino sugar compound, it is preferable to first adjust the pH of the culture to acidic and neutralize it to obtain a culture solution.Then, this culture solution is treated with a cation exchange resin such as Amberlite.
The active substance was charged and adsorbed onto an IRC-50 (NH 4 + type) column, from which the active substance was eluted with 2N ammonia water, the eluate was further concentrated, the pH was adjusted, and the active substance was added to a cation exchange resin. for example
Charge and adsorb onto a column of CM-Sephadex C-25 (NH 4 + type), elute with aqueous ammonia with a concentration gradient of 0 to 0.35N,
The active fraction is obtained, concentrated under reduced pressure, and lyophilized to obtain a purified white powder of G-367-1 in the form of a free base. Furthermore, G-367-1 obtained in this manner can easily be found to show a single spot in thin layer chromatography. Next, the present invention will be specifically explained with reference to Examples, but the present invention is not limited thereto in any way. Example 1 Dextrin 1%, glucose 1%, casein hydrolyzate 0.5%, yeast extract 0.5%, calcium carbonate
100 ml of a medium containing 0.1% (PH7.0) was dispensed into a 500 ml Erlenmeyer flask and sterilized by heating at 120°C for 20 minutes. One platinum loop from a slant culture of Dactyrosporandium thailandense strain G367 was inoculated into 10 bottles of this medium, and cultured with shaking at 30°C for 120 hours. This was then transferred to a 30-volume jar fermenter containing heat-sterilized medium 20 having the same composition as above, and cultured with aeration at 30°C for 72 hours under conditions of 300 rpm and sterile air at 20 per minute. Next, 5% dextrin, 0.5% glucose, 3% defatted soy flour, 0.7% calcium carbonate, and cobalt chloride.
Heat-sterilized medium containing 1.3ppm (PH7.2)
Culture 10 of the above into a 250 volume tank containing 200
transplanted, 30℃, 120 hours, 250 rpm, 100 rpm
Culture with aeration and agitation under sterile air conditions, and culture approx.
Got 190. Next, as in Example 2, G-367-1 was isolated and purified from the culture. Example 2 The culture obtained in Example 1 was adjusted to pH 2 with a 12N sulfuric acid aqueous solution, stirred for 30 minutes, adjusted to pH 7.0 with concentrated ammonia water, and further added with perlite as a super-aid. (Product name) 4Kg was added and filtered, and then the resulting culture solution was mixed with Amberlite.
IRC-50 (Rohm & Haas) NH 4 +
The column was charged to a column packed with Type) 10, washed with water, and eluted with 2N ammonia water 20 to obtain the entire eluate, which was concentrated under reduced pressure to 100 ml. Next, this concentrated solution was adjusted to pH 7.0 with 6N sulfuric acid aqueous solution, and then added to CM-Sephadex G-25.
(Manufactured by Pharmacia Huain Chemical Co.)
A column (diameter 4 cm) packed with 500 ml (NH 4 + form) was charged to adsorb the active substance. After washing the column with water, the column was eluted with aqueous ammonia 5 with a concentration gradient of 0 to 0.35N, and the eluate was
It was fractionated into 20 ml portions. For each fraction, chloroform: methanol: 28% ammonia water = 1:1:1
Thin layer chromatography was performed using the lower layer as a developing solvent, and the target product was confirmed by ninhydrin color development. As a result, the 185th fraction from the 175th fraction was G-
It contained only 367-1. The fractions were then collected, combined, concentrated under reduced pressure, and then lyophilized to obtain a white powder, which was further dried under reduced pressure at 40°C for 48 hours in the presence of phosphorus pentoxide to obtain G-
750 mg of purified white powder (free base) of 367-1 was obtained.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は本発明のG―367―1の赤外部吸収ス
ペクトル、第2図は本発明のG―367―1の核磁
気共鳴スペクトル(水素核)を示す。
FIG. 1 shows the infrared absorption spectrum of G-367-1 of the present invention, and FIG. 2 shows the nuclear magnetic resonance spectrum (hydrogen nuclei) of G-367-1 of the present invention.

Claims (1)

【特許請求の範囲】 1 下記の理化学的性質を有してなるアミノ糖抗
生物質G―367―1とその無毒性酸付加塩 融点 130〜133℃ 〔α〕24 +188.9゜(C=1.0 H2O) 元素分析 実測値 理論値 C=50.14 C=50.51 H= 7.60 H= 7.84 N=14.42 N=14.73 分子量 475(マススペクトルより) 分子式 C20H37N5O8 紫外部吸収スペクトル 220〜360nmに特徴的
な極大吸収を示さず、未端吸収を示すのみであ
る 赤外部吸収スペクトル (KBr法) 3350,2920,1660,1590,1380,1140,
1100,1050,1000,950cm-1付近の各波長に
吸収帯を有す。 溶解性 水、メタノールに可溶、アセトン、ベ
ンゼン、酢酸エチル、クロロホルムに不溶、 呈色反応 ニンヒドリン反応、過マンガン酸カ
リウム脱色反応は陽性、エルソンモルガン反
応、ビウレツト反応は陰性。 色性状 白色 酸塩基の区別 塩基性 2 ダクチロスポランジウム属に属するアミノ糖
抗生物質G―367―1生産菌を培地に培養し、そ
の培養物より抗生物質G―367―1を採取するこ
とを特徴とする抗生物質G―367―1の製造法。
[Scope of Claims] 1 Amino sugar antibiotic G-367-1 and its non-toxic acid addition salt having the following physical and chemical properties Melting point 130-133°C [α] 24 D +188.9° (C= 1.0 H 2 O) Elemental analysis Actual measurement Theoretical value C = 50.14 C = 50.51 H = 7.60 H = 7.84 N = 14.42 N = 14.73 Molecular weight 475 (from mass spectrum) Molecular formula C 20 H 37 N 5 O 8 Ultraviolet absorption spectrum 220 It does not show the characteristic maximum absorption at ~360 nm, and only shows edge absorption. Infrared absorption spectrum (KBr method) 3350, 2920, 1660, 1590, 1380, 1140,
It has absorption bands at each wavelength around 1100, 1050, 1000, and 950 cm -1 . Solubility: Soluble in water and methanol, insoluble in acetone, benzene, ethyl acetate, and chloroform; Color reaction: Positive for ninhydrin reaction and potassium permanganate decolorization reaction; negative for Elson-Morgan reaction and Biuret reaction. Color property: White Acid-base distinction: Basic 2 The amino sugar antibiotic G-367-1 producing bacteria belonging to the genus Dactyrosporandium is cultured in a medium, and the antibiotic G-367-1 is collected from the culture. Characteristic method for producing antibiotic G-367-1.
JP4127479A 1979-04-04 1979-04-04 Novel aminosaccharide antibiotic g-367-1 and its preparation Granted JPS55133394A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP4127479A JPS55133394A (en) 1979-04-04 1979-04-04 Novel aminosaccharide antibiotic g-367-1 and its preparation
CA000349243A CA1140877A (en) 1979-04-04 1980-04-03 Aminoglycoside antibiotics and production thereof
GB8011265A GB2053895B (en) 1979-04-04 1980-04-03 Aminoglycoside antibiotics and their production
US06/137,292 US4297486A (en) 1979-04-04 1980-04-03 Aminoglycoside antibiotic G-367-1 and method for the production thereof
FR8007574A FR2452932A1 (en) 1979-04-04 1980-04-03 NOVEL AMINOGLYCOSIDE ANTIBIOTICS AND THEIR PRODUCTION
DE19803013210 DE3013210A1 (en) 1979-04-04 1980-04-03 NEW AMINOGLYCOSIDE ANTIBIOTICS AND METHOD FOR THEIR PRODUCTION
CH5618/80A CH648855A5 (en) 1979-04-04 1980-07-23 Aminoglycoside antibiotics and process for their preparation
BE0/201867A BE884925A (en) 1979-04-04 1980-08-26 NOVEL AMINOGLYCOSIDE ANTIBIOTIC AND METHOD FOR THE PRODUCTION THEREOF.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4127479A JPS55133394A (en) 1979-04-04 1979-04-04 Novel aminosaccharide antibiotic g-367-1 and its preparation

Publications (2)

Publication Number Publication Date
JPS55133394A JPS55133394A (en) 1980-10-17
JPS6126914B2 true JPS6126914B2 (en) 1986-06-23

Family

ID=12603856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4127479A Granted JPS55133394A (en) 1979-04-04 1979-04-04 Novel aminosaccharide antibiotic g-367-1 and its preparation

Country Status (4)

Country Link
JP (1) JPS55133394A (en)
BE (1) BE884925A (en)
CH (1) CH648855A5 (en)
DE (1) DE3013210A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907771A (en) * 1971-02-03 1975-09-23 Schering Corp Antibiotic 66-40
US3920628A (en) * 1972-10-24 1975-11-18 Schering Corp 2{41 -Deoxyaminoglycosides and 2{41 -epi-amino-3{41 -desamino derivatives thereof, methods for their manufacture and novel intermediates useful therein
EP0000473B1 (en) * 1977-06-24 1981-03-11 Scherico Ltd. Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives

Also Published As

Publication number Publication date
DE3013210A1 (en) 1980-11-20
CH648855A5 (en) 1985-04-15
BE884925A (en) 1980-12-16
JPS55133394A (en) 1980-10-17

Similar Documents

Publication Publication Date Title
EP0182315B1 (en) Novel antibiotic nk84-0218 pharmaceutical compositions containing it and process for the production of the same
JPS6317078B2 (en)
JPS6041491A (en) New antibiotic
US3987029A (en) Antibacterial antibiotics AM31α, AM31β and AM31γ
JPS6331477B2 (en)
JPS6126914B2 (en)
JPS6069085A (en) Difficidin and derivative antibacterial substance
JPS6122955B2 (en)
USRE29903E (en) Antibacterial antibiotics AM31α, AM31β and AM31γ
SU539538A3 (en) Method for producing metabolite 2776
US3974035A (en) Process for preparing a cephamycin type antibiotic substance
JPH0153675B2 (en)
JPS6123996B2 (en)
JPS6212227B2 (en)
US3734832A (en) Fermentation process for producing physostigmine
JPH0153676B2 (en)
KR830000617B1 (en) Process for preparing antibiotics sf 2050 substances
JPS6130558B2 (en)
JPS6212228B2 (en)
JPS6348284A (en) Novel antibiotic yp-02908l-a and production thereof
JPH0341089A (en) Physiologically active substance 3127
JPH06312997A (en) Ko-8119 substance and its production
JPS58111687A (en) Preparation of antibiotic fortimicin a or b
JPS63192792A (en) Novel antibiotic sf 2487 substance and production thereof
JPS6250474B2 (en)